NEWS. Andreas Lindblom, co-founder and Managing Partner at Sciety, features in the latest episode of BioStock’s podcast Health and Wealth – a podcast about investing in life science. In the episode, Andreas shares the strategy that has kept Sciety on a steady growth trajectory through ten years of investing in
PRESS RELEASE. Sciety has led a SEK 87 million financing round for Neogap Therapeutics, a Swedish clinical-stage biotech company developing personalised immunotherapy for cancer. The capital will be used to advance the company’s ongoing Phase I/II clinical trial and build the clinical data required for the next stage of development.
INSIGHT. Nerve pain has long been considered difficult to treat. Current medications often provide inadequate relief and are associated with side effects such as fatigue, dizziness, and risk of addiction. At the same time, the patient population is growing rapidly, driven primarily by diabetes-related nerve damage (neuropathy), which affects up
INSIGHT. Mental health is one of the greatest health challenges of our time. Nearly one billion people worldwide experience mental health conditions each year, yet fewer than one in ten receive adequate treatment. In Sweden, mental health issues is the leading cause of long-term sick leave and accounts for 42
PRESS RELEASE. Sciety’s portfolio company PeptiSystems has secured an investment from Rubicon Healthcare Partners, making Rubicon a new shareholder in the company. The investment strengthens PeptiSystems’ position in a rapidly growing market segment and marks the next step in its international expansion. PeptiSystems develops and sells synthesis instruments that streamline
PRESS RELEASE. Sciety has led a SEK 40 million financing round for Hälsa Hemma, a Swedish healthtech company building next-generation primary care through its proprietary, integrated care platform. Through its digiphysical model, combining digital accessibility and efficiency with personal, in-home care, Hälsa Hemma is transforming how and where primary care